TOURMALINE BIO INC. - COMMON STOCK

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

08 يناير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio added to the NASDAQ Biotechnology Index

15 ديسمبر 2023 15:00:00 بحسب Nasdaq GlobeNewswire

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

14 ديسمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire